What factors do you take into account for recommending chemo/IO vs IO/IO vs CheckMate 9LA regimen in front line therapy for PD-L1 negative advanced squamous cell carcinoma?  

How do you interpret the comparative efficacy in squamous cell subsets among the CM vs KN vs EMPOWER studies?



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution